Our Board

Genetic Signatures is governed by a Board of Directors who oversee the integrity of our business operations.

Members of our Board include:

Mike Aicher

Chair
Mr. Mike Aicher is a long-standing Executive Director at Genetic Signatures offering a wealth of industry knowledge shaped by more than 30 years in genomics and molecular diagnostics.
Mr. Aicher holds multiple executive roles with leading biotechnology companies. He is the Executive Chairman of SemiconBio, a molecular electronics company digitising biology to elucidate, diagnose and treat disease, and serves as an Executive Director at SOLVD Health, an organization dedicated to addressing the opioid crisis. He also serves on the Board of Directors for Techcyte, a provider of AI-powered diagnostic technology, and PixCell Medical, a portable point of care diagnostic instrument platform.

Mr. Aicher was a Founder of Alveo Technologies, a company focused on solving global health challenges, and previously served on the boards of Fabric Genomics (later acquired by GeneDX, NASDAQ: WGS) and Ariosa Diagnostics (acquired by Roche in 2015). Mr. Aicher cofounded and served as CEO of the National Genetics Institute (NGI) from 1991 to 2013. NGI became a wholly-owned subsidiary of Labcorp (NYSE: LH) in 2000, where he led the company’s Esoteric Business Units, generating over $1 billion in annual revenue.

Mr. Aicher holds a Bachelor of Science in Business Administration from the University of Redlands, is certified as a Global Biotechnology Executive by the University of California, Berkeley, and is a recipient of Ernst & Young’s Entrepreneur of the Year award for emerging technologies.
Read More
Dr John Melki

Dr John Melki

Non-Executive Director

Dr John Melki rejoined the Genetic Signatures Board in October 2026, having previously served as Chief Executive Officer and Managing Director from 2011 to 2024. He is currently the co-founder, CEO and Managing Director of MiND Biosciences, a biotechnology company developing molecular biomarkers for neurodegenerative diseases, initially focused on motor neurone disease (MND/ALS).


John has more than 20 years of experience in biotechnology, molecular diagnostics and commercialisation. He joined Genetic Signatures in 2003 as Senior Principal Research Scientist and subsequently led the company's transformation from a small Australian biotechnology business into an international molecular diagnostics company. Under his leadership, Genetic Signatures listed on the ASX in 2015, raised more than $75 million in equity capital and expanded from five employees to more than 100, establishing operations in Australia, the United States, the United Kingdom and Germany. He oversaw the global commercialisation of the company's proprietary 3base® technology and EasyScreen™ diagnostic products, generating more than $113 million in cumulative revenue from FY16 to FY24, as well as the company’s first FDA product clearance.


John holds a BSc from the University of New South Wales and a PhD from the University of Sydney, where his doctoral research received the Peter Bancroft Prize. His research contributed to the scientific foundations of 3base® technology. He has authored more than 20 peer-reviewed publications and is named as an inventor on more than 10 patent applications.

Read More
jen harry

Dr Jenny Harry

Non-Executive Director
Dr Jenny Harry has had 25 years’ experience in executive roles and as an independent Director in leading early-stage companies to develop and commercialise innovative products. She co-founded Proteome Systems Limited with the team who pioneered the scientific field of proteomics and commercialised a suite of disruptive technologies including reagents, instrumentation and software in Australia, the USA and Japan. As CEO of Tyrian Diagnostics Ltd she secured agreements with multi-national companies for the development and commercialisation of agricultural and clinical diagnostic products.


Jenny has served on the Boards of companies in the technology, pharmaceutical and creative industries. She is a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX:NEU) and  Aeris Environmental Ltd (ASX:AEI). She joined the Neuren Board in 2018. During the ensuing 6-year period, the Company has achieved enterprise growth from $170m to ~$2B and in 2023 the Company was elevated to the ASX200 index.

Jenny holds a PhD in developmental biology, and is a graduate of the Harvard Business School’s General Management Program and the Australian Institute of Company Directors.
Read More
anne lockwood board member

Anne Lockwood

Non-Executive Director
Mrs Lockwood has over 30 years’ experience in various finance, risk management and audit roles including deep experience in mergers and acquisitions across a range of industries. Mrs Lockwood is the former Chief Financial and Commercial Officer of ASX-listed Integral Diagnostics (ASX: IDX) and is the former the Chief Financial Officer of privately owned Planet Innovation, and Non-Executive Director of Mayne Pharma Group Limited. Mrs Lockwood has spent over 20 years in accounting and audit roles including 18 years at Arthur Andersen and Ernst Young. Anne holds a Bachelor of Commerce degree with majors in accounting and law, is a chartered accountant, a fellow of the Institute of Chartered Accountants and a graduate of the Australian Institute of Company Directors.